SAN RAFAEL, Calif.,
June 23, 2020 /PRNewswire/ --
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that
Henry Fuchs, M.D., President,
Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer,
will participate in the BofA Securities 2020 Napa Biopharma
Conference on June 24, 2020 at
11:30am ET. An audio webcast of
the presentation will be available live. You can access the webcast
at: https://investors.biomarin.com/. An archived version of the
remarks will also be available through the Company's website for a
limited time following the conference.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for people with serious and
life-threatening rare disorders. The company's portfolio consists
of six commercialized products and multiple clinical and
pre-clinical product candidates.
For additional information, please visit www.biomarin.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
|
Contacts:
|
|
|
Investors
|
Media
|
|
Traci
McCarty
|
Debra
Charlesworth
|
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference-301080544.html
SOURCE BioMarin Pharmaceutical Inc.